Vnitr Lek 2016, 62(11):929-932

Notes on the HOPE-3 study

Vladimír Soška^1,2

¹ Oddělení klinické biochemie, ICRC - oddělení kardiovaskulárních chorob FN u sv. Anny v Brně

² Katedra laboratorních metod LF MU Brno a II. interní klinika LF MU a FN u sv. Anny v Brně

The study HOPE-3 aimed to determine whether treatment with statin and with antihypertensive drugs (candesartan and hydrochlorothiazide) in routine clinical practice in people without cardiovascular diseases (men aged over 55, women over 65 years) will reduce cardiovascular events. Another objective was to answer whether the effect of the above-mentioned treatment will be the same in different ethnic (anthropometric) populations. All drugs were administered as an "polypills". The study demonstrated that use of antihypertensive medication in this population does not reduce the incidence of cardiovascular events. In contrast, statin treatment reduced cardiovascular events statistically highly significant (p = 0.002). The effect of treatment was the same for all ethnic groups included to the study (total of 6 continents).

Keywords: antihypertenzive drugs; cardiovascular prevention; dyslipidemia; hypertension; statins

Received: October 6, 2016; Accepted: November 1, 2016; Published: November 1, 2016  Show citation